Took a look at this, MATH+1 appears to be less effective in mechanical ventilator dependent patients, with a survival rate of 33% in one study (1.). This contrasts to our trials where the eligibility criteria is patients "requiring mechanical ventilatory support".
The crucial factor with the MATH+1 protocol and its effectiveness is the timing of its application - needs to applied early to demonstrate higher success according to sources online. I think there's yet to be any reports with sufficient data demonstrating how effective this protocol has been (and under what criteria/circumstances), we shall see.
Remestemcel-L has shown positive results in the worst scenarios (and the interim readout hopefully confirms this), so I'd say we're in the green.
Coming News ???, page-285
-
- There are more pages in this discussion • 226 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.14 |
Change
0.050(4.59%) |
Mkt cap ! $1.301B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.14 | $1.08 | $6.654M | 5.972M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1330 | $1.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 171164 | 10 |
View Market Depth
| Last trade - 16.10pm 18/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |